0.4595  -0.019 (-3.87%)		04-24 16:00
Open: 0.47 High: 0.477 Volume: 168,872		Pre. Close: 0.478 Low: 0.4007 Market Cap: 41(M)

Short term
Mid term
Targets	6-month :	0.72	1-year :	0.87
Resists	First :	0.61	Second :	0.75
Pivot price	0.53
Supports	First :	0.4	Second :	0.33
MAs	MA(5) :	0.47	MA(20) :	0.56
	MA(100) :	0.73	MA(250) :	2.61
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	16	D(3) :	9.5
RSI	RSI(14): 29.4
52-week	High :	6.44	Low :	0.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ APLM ] has closed above bottom band by 7.2%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.48 - 0.48	0.48 - 0.48
Low:	0.4 - 0.4	0.4 - 0.4
Close:	0.46 - 0.46	0.46 - 0.46

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

Wed, 10 Apr 2024
Apollomics, Inc. (NASDAQ:APLM) Short Interest Update - MarketBeat

Wed, 03 Apr 2024
Equities Analysts Set Expectations for Apollomics, Inc.'s Q1 2024 Earnings (NASDAQ:APLM) - MarketBeat

Mon, 01 Apr 2024
Apollomics (NASDAQ:APLM) Price Target Cut to $5.00 - MarketBeat

Mon, 01 Apr 2024
EF Hutton cuts Apollomics stock price target, cites FDA approval uncertainty - Investing.com

Thu, 28 Mar 2024
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results - GlobeNewswire

Thu, 28 Mar 2024
Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	90 (M)
Held by Insiders	5.214e+007 (%)
Held by Institutions	32 (%)
Shares Short	44 (K)
Shares Short P.Month	0 (K)

EPS	-5.345e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-8 %
Return on Assets (ttm)	368.4 %
Return on Equity (ttm)	-50.8 %
Qtrly Rev. Growth	821000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.4 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-43 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	1.28

Dividend	0
Forward Dividend	155140
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.